Core Insights - The 2024 "Annual Report on Progress of New Drug Registration Clinical Trials in China" indicates a significant increase in drug clinical trial registrations, reaching 4,900, a year-on-year growth of 13.9% [2] - The report highlights that domestic pharmaceutical companies are actively engaged in clinical research, with 92.8% of the new trials initiated by domestic sponsors [2] Summary by Categories Overall Clinical Trial Registration - In 2024, the total number of drug clinical trial registrations in China reached 4,900, with new drug trials accounting for 2,539, representing 51.8% of the total [2] - The efficiency of clinical trial registration and implementation has improved compared to 2023, with average registration times for new drug trials reduced to 67.4 days [6] Drug Types and Categories - Chemical drugs dominate the clinical trials, making up over 70% of the total, while biological products account for 21.1% [4] - Among new drug trials, Class I registered drugs constitute 68.3%, with Phase I trials representing 46.92% of the total [4] Focus Areas in Clinical Trials - Antitumor drugs have the highest representation in clinical trials, with chemical drugs accounting for 24.7% and biological products for 43.1% [7] - The report indicates a notable increase in clinical trials for cell and gene therapies, with a growth rate exceeding 40% for newly registered trials [9][11] Pediatric and Rare Disease Drug Development - The number of clinical trials for pediatric and rare disease drugs has increased, with pediatric trials totaling 249, representing 9.8% of the new drug trials [14] - Rare disease drug trials reached 121, with a focus on blood system diseases, neurological diseases, and antitumor drugs, which together accounted for 63.6% of the total [16]
让患者有更多用药选择 抗肿瘤等领域新药研发再提速
Yang Shi Xin Wen·2025-07-18 00:06